AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31350995 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy (abacavir/lamivudine/dolutegravir)
Number of subjects: 64
Study 31350995 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy (abacavir/lamivudine/dolutegravir)
Number of subjects: 64
Study 31350995 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy (dolutegravir)
Number of subjects: 64
Study 31350995 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy (tenofovir/emtricitabine + a third agent)
Number of subjects: 64
Study 31350995 — intervention group
Group type: EXPERIMENTAL
Intervention: LDR (Low Drug Regimen)
Number of subjects: 64
Study 31350995 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy
Number of subjects: 64
Study 31501110 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging intervention for tobacco cessation
Number of subjects: 57
Study 28886856 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 28
Study 28886856 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 28
Study 26951842 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge-attitude-behaviour health education model
Number of subjects: 86
Study 26951842 — intervention group
Group type: COMPARATOR
Intervention: Usual care and general education models
Number of subjects: 86
Study 25106094 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace-oriented intervention
Number of subjects: 68
Study 25106094 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68
Study 25106094 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace-oriented intervention (younger subgroup)
Number of subjects: 68
Study 25106094 — intervention group
Group type: COMPARATOR
Intervention: Control group (younger subgroup)
Number of subjects: 68
Study 25106094 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace-oriented intervention (older subgroup)
Number of subjects: 68
Study 25106094 — intervention group
Group type: COMPARATOR
Intervention: Control group (older subgroup)
Number of subjects: 68
Study 25106094 — intervention group
Group type: EXPERIMENTAL
Intervention: Part-time sick leave
Number of subjects: 68
Study 22257503 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint-induced movement therapy
Number of subjects: 24
Study 22257503 — intervention group
Group type: COMPARATOR
Intervention: Bobath Concept
Number of subjects: 24
Study 19232039 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized formoterol fumarate inhalation solution (Perforomist, FFIS 20g BID)
Number of subjects: 109
Study 19232039 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium and albuterol combined in a metered-dose inhaler (MDI) (Combiventy, IPR-ALB, QID)
Number of subjects: 109
Study 17925883 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate transdermal system (MTS) applied on the hip for nine hours.
Number of subjects: 0
Study 17925883 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate transdermal system (MTS)
Number of subjects: 0
Study 17250775 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamphetamine (10 mg)
Number of subjects: 37
Study 17250775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 14667790 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem 1 g once daily
Number of subjects: 363
Study 14667790 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin-tazobactam 13.5 g divided Q6H
Number of subjects: 363
Study 11007053 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal failure (defined as plasma creatinine > 130 μmol/1)
Number of subjects: 775
Study 11007053 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate renal failure, hypercalcaemia, low Bence-Jones protein excretion
Number of subjects: 775
Study 11007053 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysis
Number of subjects: 775
Study 11007053 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversibility of renal failure
Number of subjects: 775
Study 11007053 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal failure
Number of subjects: 775
Study 11007053 — intervention group
Group type: EXPERIMENTAL
Intervention: High age, stage III disease, hypercalcaemia
Number of subjects: 775
Study 8832312 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard needle points
Number of subjects: 0
Study 8832312 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle with a protective point
Number of subjects: 0
Study 1621656 — intervention group
Group type: EXPERIMENTAL
Intervention: A-DTP
Number of subjects: 316
Study 1621656 — intervention group
Group type: COMPARATOR
Intervention: W-DTP
Number of subjects: 316
Study 6391862 — intervention group
Group type: EXPERIMENTAL
Intervention: Single layer anastomoses
Number of subjects: 165
Study 6391862 — intervention group
Group type: COMPARATOR
Intervention: Two layer anastomoses
Number of subjects: 165
Study 6391862 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 165
Study 31282325 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty liver disease prevalence in adults
Number of subjects: 294603
Study 31282325 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty liver disease prevalence in males
Number of subjects: 294603
Study 31282325 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty liver disease prevalence in females
Number of subjects: 294603
Study 31282325 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty liver disease prevalence in smokers
Number of subjects: 294603
Study 31282325 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty liver disease prevalence in alcohol users
Number of subjects: 294603
Study 31282325 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty liver disease prevalence in patients with hypertension
Number of subjects: 294603
Study 31282325 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty liver disease prevalence in patients with diabetes
Number of subjects: 294603
Study 31282325 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty liver disease prevalence in patients with coronary heart disease
Number of subjects: 294603
Study 31282325 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for fatty liver disease
Number of subjects: 294603
Study 28328759 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ropivacaine (1% ropivacaine)
Number of subjects: 160
Study 26398959 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral Elliptical (LE)
Number of subjects: 16
Study 26398959 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Elliptical (SE)
Number of subjects: 16
Study 26398959 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill Running (TR)
Number of subjects: 16
Study 24407915 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance and gait training with augmented feedback (BAL)
Number of subjects: 51
Study 24407915 — intervention group
Group type: COMPARATOR
Intervention: Lower-limb strength training (CON)
Number of subjects: 51
Study 22014897 — intervention group
Group type: EXPERIMENTAL
Intervention: Omitting elective nodal irradiation (ENI) during thoracic irradiation with concurrent chemo-radiotherapy
Number of subjects: 38
Study 22014897 — intervention group
Group type: EXPERIMENTAL
Intervention: Omitting ENI
Number of subjects: 38
Study 19092550 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle program (enhanced standard care and six NP sessions)
Number of subjects: 58
Study 19092550 — intervention group
Group type: COMPARATOR
Intervention: Enhanced standard care program (one NP and one nutrition session)
Number of subjects: 58
Study 19092550 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle program
Number of subjects: 58
Study 19092550 — intervention group
Group type: COMPARATOR
Intervention: Enhanced standard care
Number of subjects: 58
Study 17923032 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective COX-2 inhibitors
Number of subjects: 5708
Study 15059505 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene hydrochloride (RLX) 60 mg/day for 12 months
Number of subjects: 204
Study 15059505 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 11586032 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal intake of omega-3 fatty acids (cod-liver oil)
Number of subjects: 0
Study 11586032 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancies complicated by moderate preeclampsia
Number of subjects: 0
Study 11586032 — intervention group
Group type: COMPARATOR
Intervention: Control groups (not specified)
Number of subjects: 0
Study 9638964 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg
Number of subjects: 113
Study 9638964 — intervention group
Group type: COMPARATOR
Intervention: Fluvastatin 20 mg
Number of subjects: 113
Study 9638964 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg (after dose increase)
Number of subjects: 113
Study 9638964 — intervention group
Group type: COMPARATOR
Intervention: Fluvastatin 40 mg (after dose increase)
Number of subjects: 113
Study 9638964 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 113
Study 9638964 — intervention group
Group type: COMPARATOR
Intervention: Fluvastatin
Number of subjects: 113
Study 7620219 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroimidazoles (misonidazole, metronidazole, benznidazole, desmethylmisonidazole, etanidazole, pimonidazole, nimorazole, ornidazole, RSU 1069)
Number of subjects: 7000
Study 2726115 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-amniotic saline instillation
Number of subjects: 106
Study 2726115 — intervention group
Group type: COMPARATOR
Intervention: Vaginal prostaglandin E2 (3 mg)
Number of subjects: 106
Study 31479549 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab (IXE) 80 mg every 2 weeks (Q2W)
Number of subjects: 0
Study 31479549 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab (IXE) 80 mg every 4 weeks (Q4W)
Number of subjects: 0
Study 31479549 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab (IXE)
Number of subjects: 0
Study 31479549 — intervention group
Group type: COMPARATOR
Intervention: Etanercept 50 mg twice weekly
Number of subjects: 0
Study 31479549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27453334 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-anodal tDCS
Number of subjects: 8
Study 27453334 — intervention group
Group type: COMPARATOR
Intervention: Post-sham tDCS
Number of subjects: 8
Study 25943662 — intervention group
Group type: EXPERIMENTAL
Intervention: IV with oral glycerol (50% IV fluid, 50% oral fluid with added glycerol 1.5g/kg)
Number of subjects: 9
Study 25943662 — intervention group
Group type: EXPERIMENTAL
Intervention: IV (50% IV fluid, 50% oral fluid)
Number of subjects: 9
Study 25943662 — intervention group
Group type: EXPERIMENTAL
Intervention: oral glycerol (oral fluid with added glycerol 1.5g/kg)
Number of subjects: 9
Study 25943662 — intervention group
Group type: COMPARATOR
Intervention: oral (oral fluid only)
Number of subjects: 9
Study 25943662 — intervention group
Group type: EXPERIMENTAL
Intervention: IV and IV with oral glycerol
Number of subjects: 9
Study 25943662 — intervention group
Group type: EXPERIMENTAL
Intervention: IV with oral glycerol
Number of subjects: 9
Study 25943662 — intervention group
Group type: EXPERIMENTAL
Intervention: IV trials
Number of subjects: 9
Study 24580125 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinetic oscillation stimulation (KOS) at low frequency of the nasal mucosa
Number of subjects: 86
Study 24580125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 22553403 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG (500 mL ingested within 2 hours starting 30 minutes after swallowing the capsule)
Number of subjects: 44
Study 22553403 — intervention group
Group type: COMPARATOR
Intervention: No additional preparation (control group A)
Number of subjects: 44
Study 19241301 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive FP service package (individual counselling, free contraceptive materials, involvement of male partner)
Number of subjects: 2336
Study 19241301 — intervention group
Group type: COMPARATOR
Intervention: Simple FP service package (limited information and referral to existing FP services)
Number of subjects: 2336
Study 17530969 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic plyometric training
Number of subjects: 21
Study 17530969 — intervention group
Group type: EXPERIMENTAL
Intervention: Land plyometric training
Number of subjects: 21
Study 17530969 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 21
Study 15447015 — intervention group
Group type: EXPERIMENTAL
Intervention: Autofluorescence spectroscopy with PCA, artificial neural networks, and red/green intensity ratios; multiple normalization techniques applied.
Number of subjects: 269
Study 12070931 — intervention group
Group type: EXPERIMENTAL
Intervention: Early cholecystectomy
Number of subjects: 240
Study 12070931 — intervention group
Group type: COMPARATOR
Intervention: Delayed cholecystectomy
Number of subjects: 240
Study 10696419 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg quinine salt/kg bodyweight daily for 7 days
Number of subjects: 122
Study 10696419 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg quinine salt/kg bodyweight daily for 7 days
Number of subjects: 122
Study 10696419 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg quinine salt/kg bodyweight daily for 7 days
Number of subjects: 122
Study 7647179 — intervention group
Group type: EXPERIMENTAL
Intervention: P300 amplitude for large digits
Number of subjects: 14
Study 7647179 — intervention group
Group type: EXPERIMENTAL
Intervention: Reaction time (RT) for large digits
Number of subjects: 14
Study 7647179 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of errors for large digits
Number of subjects: 14
Study 7647179 — intervention group
Group type: EXPERIMENTAL
Intervention: P300 amplitude for small digits
Number of subjects: 14
Study 2286000 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (3 or 4 g per day for 2 or 3 days)
Number of subjects: 76
Study 2286000 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol (14 days)
Number of subjects: 76
Study 2286000 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 76
Study 2286000 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol
Number of subjects: 76
Study 7027872 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Number of subjects: 0
Study 30632890 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced counseling with visual representations of risk
Number of subjects: 66
Study 30632890 — intervention group
Group type: COMPARATOR
Intervention: Standard counseling
Number of subjects: 66
Study 28272312 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesoglycan
Number of subjects: 0
Study 26059981 — intervention group
Group type: EXPERIMENTAL
Intervention: rLH 150 IU/day administered at GnRH-ant administration
Number of subjects: 40
Study 26059981 — intervention group
Group type: EXPERIMENTAL
Intervention: rLH 150 IU/day administered from the start of rFSH administration
Number of subjects: 40
Study 26059981 — intervention group
Group type: EXPERIMENTAL
Intervention: rLH 75 IU/day administered at GnRH-ant administration
Number of subjects: 40
Study 26059981 — intervention group
Group type: EXPERIMENTAL
Intervention: rLH 75 IU/day administered from the start of rFSH administration
Number of subjects: 40
Study 26059981 — intervention group
Group type: EXPERIMENTAL
Intervention: rLH 150 IU/day administered at rFSH administration
Number of subjects: 40
Study 26059981 — intervention group
Group type: EXPERIMENTAL
Intervention: rLH 75 IU/day administered at rFSH administration
Number of subjects: 40
Study 24618336 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin (75 mg/m² by intravenous bolus on day 1 or 72 h continuous intravenous infusion)
Number of subjects: 455
Study 24618336 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin plus ifosfamide (Doxorubicin 75 mg/m²; 25 mg/m² per day, days 1-3 plus ifosfamide 10 g/m² over 4 days with mesna and pegfilgrastim)
Number of subjects: 455
Study 24618336 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin plus ifosfamide
Number of subjects: 455
Study 24618336 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 455
Study 22118808 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 80
Study 22118808 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 80
Study 22118808 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavior Therapy (CBT) or Escitalopram
Number of subjects: 80
Study 19751298 — intervention group
Group type: EXPERIMENTAL
Intervention: T4 (Thyroxine)
Number of subjects: 1265
Study 19751298 — intervention group
Group type: COMPARATOR
Intervention: Not on T4 (Control)
Number of subjects: 1265
Study 19751298 — intervention group
Group type: COMPARATOR
Intervention: Not on T4 (Males)
Number of subjects: 1265
Study 19751298 — intervention group
Group type: COMPARATOR
Intervention: Not on T4 (Females)
Number of subjects: 1265
Study 19751298 — intervention group
Group type: EXPERIMENTAL
Intervention: T4 (Females)
Number of subjects: 1265
Study 17855198 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral single-shot paravertebral blocks (BSS-PVB) with low-dose fentanyl and 3 mL bupivacaine 0.5% each (T1-7)
Number of subjects: 52
Study 17855198 — intervention group
Group type: COMPARATOR
Intervention: High thoracic epidural analgesia (TEA) with bupivacaine 0.125% at 10 mL/hour
Number of subjects: 52
Study 15064271 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane (DES)
Number of subjects: 40
Study 15064271 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (FEN)
Number of subjects: 40
Study 11303715 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate
Number of subjects: 13
Study 9255197 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium citrate supplementation (1.5 mmol/kg per day)
Number of subjects: 39
Study 9255197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 9255197 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium citrate supplementation
Number of subjects: 39
Study 8331334 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative Thought Reduction (NTR)
Number of subjects: 86
Study 8331334 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Thought Increment (PTI)
Number of subjects: 86
Study 8331334 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of NTR and PTI
Number of subjects: 86
Study 8331334 — intervention group
Group type: COMPARATOR
Intervention: Placebo Treatment
Number of subjects: 86
Study 8331334 — intervention group
Group type: COMPARATOR
Intervention: No Treatment
Number of subjects: 86
Study 3554879 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine
Number of subjects: 40
Study 3554879 — intervention group
Group type: COMPARATOR
Intervention: Baclofen
Number of subjects: 40
Study 3554879 — intervention group
Group type: COMPARATOR
Intervention: Tizanidine and Baclofen
Number of subjects: 40
Study 31491384 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-spectrum antibiotics administered prior and subsequent to seasonal influenza vaccination
Number of subjects: 0
Study 31491384 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-spectrum antibiotics administered to subjects with low pre-existing antibody titers
Number of subjects: 0
Study 31491384 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-spectrum antibiotics treatment
Number of subjects: 0
Study 27604371 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic dissection-based education (Group II)
Number of subjects: 112
Study 27604371 — intervention group
Group type: EXPERIMENTAL
Intervention: Both education methods (Group III)
Number of subjects: 112
Study 27604371 — intervention group
Group type: COMPARATOR
Intervention: Classroom education (Group I)
Number of subjects: 112
Study 25887998 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised e-health supported neuromuscular training program (8-week duration) in addition to usual care
Number of subjects: 0
Study 25887998 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 0
Study 23633090 — intervention group
Group type: EXPERIMENTAL
Intervention: Take-home emergency naloxone
Number of subjects: 5600
Study 23633090 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-as-usual plus take-home emergency naloxone
Number of subjects: 5600
Study 23633090 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 5600
Study 22435280 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2 mg/kg single IV bolus (Precalculated group, PG)
Number of subjects: 84
Study 22435280 — intervention group
Group type: COMPARATOR
Intervention: Titration of Propofol (Titration group, TG)
Number of subjects: 84
Study 19304092 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamellar epithelial debridement (LED)
Number of subjects: 39
Study 19304092 — intervention group
Group type: COMPARATOR
Intervention: Photorefractive keratectomy (PRK)
Number of subjects: 39
Study 17374389 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC)
Number of subjects: 18415
Study 17374389 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 18415
Study 17374389 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 18415
Study 15606472 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide/timolol fixed combination (D/T)
Number of subjects: 30
Study 15606472 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost 0.005%
Number of subjects: 30
Study 11528357 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg norethindrone acetate (NA)/5 microg ethinyl estradiol (EE)
Number of subjects: 945
Study 11528357 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg norethindrone acetate (NA)/5 microg ethinyl estradiol (EE)
Number of subjects: 945
Study 11528357 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg norethindrone acetate (NA)/10 microg ethinyl estradiol (EE)
Number of subjects: 945
Study 11528357 — intervention group
Group type: COMPARATOR
Intervention: 0.625 mg conjugated equine estrogens (CEE)/2.5 mg medroxyprogesterone acetate (MPA)
Number of subjects: 945
Study 9631672 — intervention group
Group type: EXPERIMENTAL
Intervention: Home vaccination service
Number of subjects: 405
Study 9631672 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard vaccination approach)
Number of subjects: 405